An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome

NCT04988867 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
15
Enrollment
INDUSTRY
Sponsor class

Stopped As a result of marketing approval of trofinetide on 10 March 2023, the study was terminated by the Sponsor with the intent of switching patients to commercially available product.

Conditions

Interventions

Sponsor

ACADIA Pharmaceuticals Inc.